Phase II study of epirubicin, oxaliplatin and docetaxel combination in metastatic gastric or gastroesophageal junction adenocarcinoma.

Phase II study of epirubicin, oxaliplatin and docetaxel combination in metastatic gastric or gastroesophageal junction adenocarcinoma.

Item
http://www.wikidata.org/entity/Q37134006
Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer.Benchmarking of gastric cancer sensitivity to anti-cancer drugs ex vivo as a basis for drug selection in systemic and intraperitoneal therapyFOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort.The expression and significance of P-glycoprotein, lung resistance protein and multidrug resistance-associated protein in gastric cancerDocetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study.Sunitinib reverse multidrug resistance in gastric cancer cells by modulating Stat3 and inhibiting P-gp function.The association of statins and taxanes: an efficient combination trigger of cancer cell apoptosis.DNA damage repair and survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy.Expression of the Hippo transducer TAZ in association with WNT pathway mutations impacts survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy.
P2860

Phase II study of epirubicin, oxaliplatin and docetaxel combination in metastatic gastric or gastroesophageal junction adenocarcinoma.

Item
http://www.wikidata.org/entity/Q37134006
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Phase II study of epirubicin, ...... ageal junction adenocarcinoma.
@en
Phase II study of epirubicin, ...... ageal junction adenocarcinoma.
@nl
type
label
Phase II study of epirubicin, ...... ageal junction adenocarcinoma.
@en
Phase II study of epirubicin, ...... ageal junction adenocarcinoma.
@nl
prefLabel
Phase II study of epirubicin, ...... ageal junction adenocarcinoma.
@en
Phase II study of epirubicin, ...... ageal junction adenocarcinoma.
@nl
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P478
P50
P577
P5875
P6179
P698
P921
P932
P356
P1433
P1476
Phase II study of epirubicin, ...... ageal junction adenocarcinoma.
@en
P2093
P2860
P2888
P304
P31
P356
P478
P50
P577
P5875
P6179
P698
P921
P932